AI has found wide application in the healthcare sector, for example, it is used to detect diseases, develop medicines and deliver healthcare services.
In healthcare sector, AI programs use software and algorithms for analysis of complex medical data, with higher efficiency and accuracy compared with traditional techniques for analytic and clinical decision-making.
Personalized medical care would be developed into a general trend in the future, and more data collection and analysis is needed to achieve personalized solutions.
Silicon Valley and China are seeking for cooperation in wide-ranging fields to better apply AI in healthcare.
Faced with different challenges in healthcare sector, China and the US have a unique opportunity to grab in this field.
One challenge for China is to boost investment to digitalize and label data, and make certain the relevance of all stored information.
Whilst the issue with the US is that size of data its healthcare sector collected is smaller than that collected in China. US has evident advantages in sample collection and labeling, thus data are well prepared for application in algorithm and analysis.
AI application in healthcare is a field where China and the US both boast advantages, and cooperation in which can benefit both, said Zhang Lu, a Silicon Valley-based venture capitalist specializing in AI technologies and healthcare investment, adding that, the environment for such cooperation has been rather favourable in spite of the trade spats between the two countries.
Zhang produced startup Mission Bio in Silicon Valley as a good example. The company has developed a precision genomics platform for high throughput single-cell DNA analysis. The significance of this technology is that, it can help detect small-cell lung cancer at an early stage, which is difficult to spot before it has spread.
Another example is WellSIM Biomedical Technologies. Liu Fei co-founded WellSim in 2016. He said the reason he decided to team up with Chinese players in this field is that the country is really a huge market, and the cost and procedure to make a product to hit the market are satisfactorily worthy.
His team is working on a kind of automated biomark capturing system, which aims at more efficient capturing at a lower cost. Assembling of their prototype is done in Shenzhen City of South China’s Guangdong Province, and production is expected to start soon.
As a special economic zone, Shenzhen has a thriving pool of well-educated researchers and engineers, and mature networks of supporting services.
With the aging of China’s population, aging-associated diseases and diseases caused by other factors, such as environmental pollution and pressures in modern life, the country’s healthcare market is expected to grow substantially.